PBAC's latest decision on Netupitant with palonosetron: Recommended with restriction (2023). Considered for Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2016
Submissions
2
2016 → 2023
Eligible population
Patients scheduled to receive chemotherapy regimens with high or moderate emetic risk, in combination with dexamethasone.
Therapy area
Oncology
Line of therapy
Any
Evidence base
Cost-minimisation
Economic model
BIA only
ICER note
This was a Category 4 (administrative/minor) submission requesting an amendment to clinical criteria. No new economic evaluation was performed; budget impact analysis only, with values redacted.
Submission history
Nov 2016: Recommended with restriction · Restricted
Mar 2023: Recommended with restriction · Authority Required